MET and malignant peripheral nerve sheath tumor: To advance our understanding of the MPNST therapeutic response and resistance to RAS pathway inhibition, we developed diverse preclinical NF1-related MPNST models, including an “MET-addicted” model of NF1-related MPNSTs (NF1-MET), an Nf1/Trp53-deficient model (NF1-P53), and an NF1 model (P53WT, Hgf-amplified) [7,8,9].